Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population
Conclusion: This is the first real world Lebanese data of HCV treatment with DAAs. The study population was significant for a large number of patients with cirrhotic (50%) and treatment experienced patients (42%). SVR12 was achieved in 93% of patients with no difference between treatment na ïve and experienced patients. SVR12 was lower in patients with cirrhosis compared to patients with lower stage of fibrosis (91.3% vs. 98.7%).
Source: The Journal of Infection in Developing Countries - Category: Infectious Diseases Source Type: research
More News: Blood Transusion | Cancer & Oncology | Carcinoma | Cirrhosis | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | International Medicine & Public Health | Lebanon Health | Liver Cancer | Norvir | Oral Cancer | Study | Virology